144 related articles for article (PubMed ID: 38376128)
1. Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.
Baggio D; Wellard C; Chung E; Talaulikar D; Keane C; Opat S; Giri P; Minson A; Cheah CY; Armytage T; Lee D; Chong G; Johnston A; Cochrane T; Waters N; Hamad N; Wood EM; Hawkes EA
Leuk Lymphoma; 2023 Mar; 64(3):621-627. PubMed ID: 38376128
[TBL] [Abstract][Full Text] [Related]
2. [Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].
Vorobyev VI; Gemdzhian EG; Fedorova LV; Mikhailova NB; Ilyasov RK; Kaleikina LP; Trubyakova OS; Kaplanov KD; Melnichenko EV; Martynova EV; Yakovleva EP; Li OY; Tarasenko EV; Chumakova EP; Bulieva NB; Nesterova ES; Margolin OV; Zherebtsova VA; Butaev LS; Ptushkin VV
Ter Arkh; 2021 Jul; 93(7):770-777. PubMed ID: 36286727
[TBL] [Abstract][Full Text] [Related]
3. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
Cheah CY; Chihara D; Romaguera JE; Fowler NH; Seymour JF; Hagemeister FB; Champlin RE; Wang ML
Ann Oncol; 2015 Jun; 26(6):1175-1179. PubMed ID: 25712454
[TBL] [Abstract][Full Text] [Related]
4. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.
Maruyama D; Omi A; Nomura F; Touma T; Noguchi Y; Takebe K; Izutsu K
Int J Hematol; 2024 Feb; 119(2):146-155. PubMed ID: 38195971
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S
Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
[TBL] [Abstract][Full Text] [Related]
8. Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
Mulligan SP; Opat S; Cheah CY; Kuss B; Hertzberg M; Marlton P; Poplar S; Puig A; McGeachie M; Weinkove R; Tam CS
Leuk Lymphoma; 2023 Feb; 64(2):312-318. PubMed ID: 36423351
[TBL] [Abstract][Full Text] [Related]
9. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
Sancho JM; Marín-Niebla A; Fernández S; Capote FJ; Cañigral C; Grande C; Donato E; Zeberio I; Puerta JM; Rivas A; Pérez-Ceballos E; Vale A; Martín García-Sancho A; Salar A; González-Barca E; Teruel A; Pastoriza C; Conde-Royo D; Sánchez-García J; Barrenetxea C; Arranz R; Hernández-Rivas JÁ; Ramírez MJ; Jiménez A; Rubio-Azpeitia E
Int J Hematol; 2022 Sep; 116(3):381-392. PubMed ID: 35551632
[TBL] [Abstract][Full Text] [Related]
10. Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.
Burkart M; Karmali R
J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330376
[TBL] [Abstract][Full Text] [Related]
11. Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
Portell CA; Wages NA; Kahl BS; Budde LE; Chen RW; Cohen JB; Varhegyi NE; Petroni GR; Williams ME
Blood Adv; 2022 Mar; 6(5):1490-1498. PubMed ID: 34700344
[TBL] [Abstract][Full Text] [Related]
12. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
Goto H; Ito S; Kizaki M; Yamaguchi M; Fukuhara N; Kato K; Saito T; Terui Y; Okubo S; Soshin T; Zeng J; Honda H; Badawi M; Ross JA; Izutsu K
Int J Clin Oncol; 2024 Feb; 29(2):232-240. PubMed ID: 38157190
[TBL] [Abstract][Full Text] [Related]
14. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
15. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
16. Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.
Rai S; Tanizawa Y; Cai Z; Huang YJ; Taipale K; Tajimi M
Adv Ther; 2022 Oct; 39(10):4792-4807. PubMed ID: 35984628
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.
Epperla N; Hamadani M; Cashen AF; Ahn KW; Oak E; Kanate AS; Calzada O; Cohen JB; Farmer L; Ghosh N; Tallarico M; Nabhan C; Costa LJ; Kenkre VP; Hari PN; Fenske TS
Hematol Oncol; 2017 Dec; 35(4):528-535. PubMed ID: 28066928
[TBL] [Abstract][Full Text] [Related]
18. Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
Stewart CM; Michaud L; Whiting K; Nakajima R; Nichols C; De Frank S; Hamlin PA; Matasar MJ; Gerecitano JF; Drullinsky P; Hamilton A; Straus D; Horwitz SM; Kumar A; Moskowitz CH; Moskowitz A; Zelenetz AD; Rademaker J; Salles G; Seshan V; Schöder H; Younes A; Tsui DWY; Batlevi CL
Clin Cancer Res; 2022 Jan; 28(1):45-56. PubMed ID: 34615723
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Wang ML; Jain P; Zhao S; Lee HJ; Nastoupil L; Fayad L; Ok CY; Kanagal-Shamanna R; Hill HA; Yao Y; Hagemeister FB; Westin JR; Fowler N; Samaniego F; Steiner R; Nair R; Iyer SP; Navsaria L; Badillo M; ; Feng L; Xuelin H; Nogueras Gonzalez GM; Xu G; Wagner-Bartak N; Thirumurthi S; Santos D; Tang G; Lin P; Wang SA; Jorgensen J; Yin CC; Li S; Patel KP; Vega F; Medeiros LJ; Flowers CR; Wang L
Lancet Oncol; 2022 Mar; 23(3):406-415. PubMed ID: 35074072
[TBL] [Abstract][Full Text] [Related]
20. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Wang M; Schuster SJ; Phillips T; Lossos IS; Goy A; Rule S; Hamadani M; Ghosh N; Reeder CB; Barnett E; Bravo MC; Martin P
J Hematol Oncol; 2017 Nov; 10(1):171. PubMed ID: 29096668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
